Comparison · NCT03711279-deaths
SHR-1210 Plus Apatinib vs ADM Plus IFO or IFO Alone: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. SHR-1210 Plus Apatinib vs ADM Plus IFO or IFO Alone: deaths from any cause. Trial comparisons, record NCT03711279-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03711279-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.04 | 0.011 | 0.135 | wilson | |
| Risk in group 2 | 0.0426 | 0.0117 | 0.142 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00255 | -0.107 | 0.0969 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.94 | 0.138 | 6.41 | log | |
| Odds ratio, group 1 over group 2 | 0.938 | 0.127 | 6.94 | log | |
| Number needed to treat, for one fewer death from any cause on SHR-1210 Plus Apatinib than on ADM Plus IFO or IFO Alone | 392 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | SHR-1210 Plus Apatinib | SHR-1210 200 mg q3w+ Apatinib 500 mg qd | 2 | 50 | EG000 |
| Group 2 | ADM Plus IFO or IFO Alone | ADM 60 mg/m2 D1 + IFO 2 g/m2 D1-D4 q3w；if the cumulative doses of ADM were beyond 450 mg/m2, the monotherapy of IFO (2 g/m2 D1-D5 q3w) would be used. | 2 | 47 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- 18 months
Source ClinicalTrials.gov
Trial
- Title
- A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue Sarcoma
- NCT number
- NCT03711279
- Phases
- PHASE2
- Conditions
- Sarcoma
- Interventions
- SHR-1210 plus Apatinib, ADM plus IFO or IFO alone
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Results first posted
- 2024-02-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03711279?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03711279-deaths